The association of antiplatelet agents with mortality among patients with non-COVID-19 community-acquired pneumonia: a systematic review and meta-analysis.

ABSTRACT:

Background

Community-acquired pneumonia (CAP) triggers inflammatory and thrombotic host responses driving morbidity and mortality. Antiplatelet agents may favorably modulate these pathways; however, their role in non-COVID-19 CAP remains uncertain.

Objectives

To evaluate the association of antiplatelet agents with mortality in hospitalized patients with non-COVID-19 CAP.

Methods

We conducted a systematic review and meta-analysis of observational studies and randomized controlled trials (RCTs) of adult patients hospitalized for non-COVID-19 CAP exposed to antiplatelet agents (acetylsalicylic acid or P2Y12 inhibitors). We searched MEDLINE, Embase, and CENTRAL from inception to August 2023. Our primary outcome was all-cause mortality: meta-analyzed (random-effects models

SUBMITTER: Lother SA 

PROVIDER: S-EPMC11387270 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature